PT - JOURNAL ARTICLE AU - Atzeni, Fabiola AU - Costa, Luisa AU - Caso, Francesco AU - Scarpa, Raffaele AU - Sarzi-Puttini, Piercarlo TI - Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis AID - 10.3899/jrheum.150643 DP - 2015 Nov 01 TA - The Journal of Rheumatology PG - 79--81 VI - 93 4099 - http://www.jrheum.org/content/93/79.short 4100 - http://www.jrheum.org/content/93/79.full SO - J Rheumatol2015 Nov 01; 93 AB - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents.